Comparisons of survival outcomes between bevacizumab and olaparib in BRCA-mutated, platinum-sensitive relapsed ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG 3052).,Journal of Gynecologic Oncology

当前位置： X-MOL 学术 › J. Gynecol. Oncol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Comparisons of survival outcomes between bevacizumab and olaparib in BRCA-mutated, platinum-sensitive relapsed ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG 3052).
Journal of Gynecologic Oncology ( IF 3.4 ) Pub Date : 2021-08-05 , DOI: 10.3802/jgo.2021.32.e90
Se Ik Kim ₁ , Jeong-Won Lee ₂ , Kidong Kim ₃ , Maria Lee ₁ , Jigeun Yoo ₄ , Min Chul Choi ₅ , Suhyun Hwangbo ₆ , Young Hwa Kwak ₇ , Jong-Min Lee ₈ , So-Jin Shin ₉ , Seung-Hyuk Shim ₁₀ , Min Kyu Kim ₁₁

Affiliation

Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea.
Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam, Korea.
Department of Obstetrics and Gynecology, Daejeon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Daejeon, Korea.
Comprehensive Gynecologic Cancer Center, CHA Bundang Medical Center, CHA University, Seongnam, Korea.
Interdisciplinary Program in Bioinformatics, Seoul National University, Seoul, Korea.
Department of Obstetrics and Gynecology, Institute of Women's Life Medical Science, Yonsei University College of Medicine, Seoul, Korea.
Department of Obstetrics and Gynecology, Kyung Hee University Hospital at Gangdong, Kyung Hee University School of Medicine, Seoul, Korea.
Department of Obstetrics and Gynecology, Keimyung University School of Medicine, Daegu, Korea.
Department of Obstetrics and Gynecology, Research Institute of Medical Science, Konkuk University School of Medicine, Seoul, Korea.
Department of Obstetrics and Gynecology, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea.

To compare survival outcomes between bevacizumab (BEV) and olaparib (OLA) maintenance therapy in BRCA-mutated, platinum-sensitive relapsed (PSR) high-grade serous ovarian carcinoma (HGSOC).

中文翻译：